Clinical trials: Persistent Cervical Carcinoma
Cervical Cancer
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.
- Trial name
- NCT05998941
- Testing
- TQB2868 injection, Paclitaxel injection, Cisplatin injection
- Where
- 2 sites in China
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Leydig Cell Tumor, Ovarian Sarcoma
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
The purpose of this phase I study is to determine the highest dose of carboplatin and gemcitabine (gemcitabine hydrochloride) that can be given safely to subjects with gynecologic cancer, in combination with stereotactic body…
- Conditions
- Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei
- Trial name
- NCT01652794
- Testing
- stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Cervical Cancer
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
The purpose of this study is to determine the efficacy and safety the combination of TRANSKRIP ® vs placebo plus Carboplatin/Paclitaxel as first line treatment in patients with recurrent-persistent cervical cancer.
- Trial name
- NCT02446652
- Testing
- Hydralazine/Magnesium, Carboplatin, Paclitaxel
- Where
- Mexico
- Sponsor
- National Institute of Cancerología
Cervical Cancer
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00691301
- Testing
- cisplatin, pemetrexed disodium
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Uterine Cervical Neoplasms
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
Among the immune cell therapy, autologous adoptive immune cell therapy is a method to transfer the immune cells derived from peripheral white blood cells and expanded and stimulated with various cytokines and tumor specific…
- Trial name
- NCT01194609
- Testing
- Immune cell, Low dose radiation
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Korea Cancer Center Hospital
Cervical Cancer, Recurrent Cervical Cancer
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Drug: Cabozantinib Drug: Pembrolizumab
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04230954
- Testing
- Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of South Alabama
Head and Neck Cancer
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine.
- Trial name
- NCT00004062
- Testing
- azacitidine, liothyronine sodium, iodine I 131
- Where
- United States
- Sponsor
- Lucille P. Markey Cancer Center at University of Kentucky
Cervical Cancer
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced…
- Trial name
- NCT00016926
- Testing
- capecitabine
- Where
- 10 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Vaginal Cancer
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced…
- Trial name
- NCT00002562
- Testing
- paclitaxel
- Where
- 50 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT05179239
- Testing
- SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Trial name
- NCT00025233
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
- Trial name
- NCT05838521
- Testing
- Sacituzumab govitecan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Cervix Cancer
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of topotecan when given weekly with cisplatin in patients with persistent, recurrent, or advanced stage cervical cancer.
- Trial name
- NCT00322920
- Testing
- Topotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Cervical Cancer Stage IVB
A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The study medications were used as follows: 1 cycle every 21 days (3 weeks) of the following regimen. Test drug: QL1706, HPV 9-valent vaccine QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on Day 1 of each…
- Trial name
- QL1706 (NCT06882447)
- Testing
- Trial drug: QL1706, HPV 9-valent vaccine
- Volunteers
- 35 people
- Sponsor
- Northern Jiangsu People's Hospital
Stage IVB Cervical Cancer, Recurrent Cervical Cancer
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04974944
- Testing
- Camrelizumab, Apatinib, Paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease
- Trial name
- NCT01267253
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 43 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Ovarian Carcinoma
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer
- Trial name
- NCT06677190
- Testing
- Belzutifan
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Cervical Cancer
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have persistent or…
- Trial name
- NCT00006224
- Testing
- gemcitabine hydrochloride
- Where
- 39 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors
- Trial name
- NCT05290935
- Testing
- Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Lei Li
Cervical Cancer
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087126
- Testing
- topotecan hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group